ABNX.PA ABIONYX Pharma EURONEXT +5.01% intraday 10 Mar 2026 ahead of earnings: watch CER-001

ABNX.PA stock jumped 5.01% intraday to EUR 3.46 on 10 Mar 2026 as investors position ahead of ABIONYX Pharma SA’s earnings scheduled for 12 Mar 2026. We see trading activity lift volume to 127,136.00 shares versus a 30‑day average of 153,900.00. The short-term move reflects focus on clinical readouts for CER-001 and liquidity sensitivity in small-cap biotech names on EURONEXT.

Earnings timeline and ABNX.PA stock catalysts

ABNX.PA’s earnings announcement is set for 12 Mar 2026. Investors will watch revenue, cash runway commentary, and any updates on CER-001 and CER-002 programs. A clear readout or timeline for clinical milestones could move the stock beyond the day range of EUR 3.31–3.48.

Intraday price action and technical snapshot for ABNX.PA stock

The stock trades at EUR 3.46, up 5.01% on volume of 127,136.00. The 50‑day average is EUR 3.62 and 200‑day average is EUR 3.00. RSI sits at 41.48, suggesting room for either recovery or further pullback. Traders should note the day high EUR 3.48 and day low EUR 3.31 as immediate reference points.

Fundamentals and valuation — ABNX.PA stock review

ABIONYX reports EPS of -0.13 and a trailing PE of -25.15, reflecting losses typical for development-stage biotech. Market cap is EUR 115,292,914.00 with book value per share EUR 0.16 and cash per share EUR 0.10. Price/sales sits at 26.35, well above Healthcare sector medians, and signals market pricing for future success rather than current sales.

Meyka Grade and ABNX.PA stock forecast

Meyka AI rates ABNX.PA with a score of 65.37 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly target of EUR 5.87, versus the current EUR 3.46, implying upside of 69.62%. Forecasts are model-based projections and not guarantees.

Technical levels, price targets, and trading scenarios for ABNX.PA stock

We set scenario targets: conservative EUR 4.50, base EUR 5.87 (Meyka model), and bull EUR 10.44 (three‑year view). Immediate support lies near EUR 3.00 (200‑day MA) and resistance near EUR 3.70–3.80 (Bollinger upper). ATR is EUR 0.16, so expect intraday swings of roughly ±0.16. Low liquidity increases gap risk around earnings.

Risks and opportunities in the ABNX.PA stock outlook

Opportunity stems from successful CER‑001 data or clearer partnerships that extend runway. Risks include continued negative EPS, thin trading (avg vol 153,900.00), and valuation metrics such as PB 20.94 and P/S 26.35 that imply high outcome dependency. Sector headwinds for Healthcare versus broader market mean biotech-specific news will drive moves.

Final Thoughts

ABNX.PA stock trades at EUR 3.46 intraday on 10 Mar 2026, reflecting short-term positioning ahead of ABIONYX Pharma SA’s earnings on 12 Mar 2026. Our analysis balances pipeline upside against stretched valuation and limited liquidity. Meyka AI’s forecast model projects a yearly target of EUR 5.87, implying ~69.62% upside versus the current price. We propose scenario targets: EUR 4.50 (conservative), EUR 5.87 (base), and EUR 10.44 (bull, multi‑year). Technicals show support around the EUR 3.00 200‑day MA and resistance near EUR 3.70–3.80. Remember, the company posts a negative EPS of -0.13 and a trailing PE of -25.15, so short-term earnings outcomes and clinical updates will be decisive. Use position sizing that reflects high volatility and binary event risk. For deeper company context see Meyka AI’s real‑time page for ABNX.PA at Meyka stock page. For peer comparisons and market notes consult external coverage from Investing.com ABIONYX compare and Investing.com Genfit compare. Meyka AI provides this as data-driven market analysis and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.